Objective: To quantify polyneuropathy impairments and comorbidities utilizing the Rochester Epidemiology Project (2010 census 5 148,201).Methods: ICD-9-CM coding identified polyneuropathy cases (2006)(2007)(2008)(2009)(2010) and their 5:1 age-and sex-matched controls. Mortality and impairments were evaluated while identifying and adjusting for Charlson Index comorbidities.Results: Overall prevalence of polyneuropathy was 1.66%, and markedly rose to 6.6% in persons older than 60 years. Cases (n 5 2,892) had more comorbidities than controls (n 5 14,435) with higher median Charlson Index (6 vs 3, p , 0.001). Diabetes with end-organ disease represented the largest increased comorbidity in cases compared with controls (46.8% vs 6.5%). Diabetic polyneuropathy was the most common specific subtype (38.2%). Miscoded idiopathic cases and false-negative controls also commonly had diabetic polyneuropathy. Median modified Rankin Scale score was considerably higher for cases than controls (4 vs 1, p , 0.001). Multiple comorbidities were found associated with polyneuropathy after adjusting for diabetes co-occurrence, including pulmonary disease, dementia, and others. Polyneuropathy was an independent contributor to multiple functional impairments including difficulty walking (odds ratio [OR] 5 1.9), climbing stairs (OR 5 2.0), using an assistive device (OR 5 2.0), fall tendency (OR 5 2.4), work disability (OR 5 4.2), lower limb amputations (OR 5 3.9), and opioid use (OR 5 2.7). Prevalent cases had a younger median age at death than controls (80 vs 86 years, p , 0.001), and incident cases had a 6-month shorter survival. Conclusions:Polyneuropathies have notable neurologic impairments beyond their identified multiple comorbidities. Life expectancy is shortened. Diabetic polyneuropathy is underidentified. The quantified extent of the disease burden and refined comorbidity associations emphasize that greater research efforts and health care initiatives are needed. Neurology ® 2015;84:1644-1651 GLOSSARY ADL 5 activities of daily living; CI 5 confidence interval; CPT 5 current procedural terminology; ICD-9-CM 5 International Classification of Diseases, Ninth Revision, Clinical Modification; IQR 5 interquartile range; mRS 5 modified Rankin Scale; OR 5 odds ratio; REP 5 Rochester Epidemiology Project.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.